Pemetrexed in malignant pleural mesothelioma

Area of Science:

• Oncology
• Thoracic Medicine
• Pharmacology

Background:

• Malignant pleural mesothelioma (MPM) is an aggressive cancer with a poor prognosis.
• Limited treatment options and drug efficacy have historically challenged MPM management.
• Antifolate drugs, particularly newer agents, represent a promising therapeutic avenue.

Purpose of the Study:

• To evaluate the efficacy and safety of pemetrexed (Alimta) in treating malignant pleural mesothelioma.
• To compare the therapeutic benefits of pemetrexed-based regimens against standard chemotherapy.

Main Methods:

• A phase II trial assessed pemetrexed as a single agent in MPM patients.
• A large, randomized phase III trial compared pemetrexed/cisplatin combination therapy with cisplatin monotherapy.
• Quality of life and pulmonary function were secondary endpoints.

Main Results:

• In the phase II trial, pemetrexed monotherapy showed a median overall survival of 10.7 months.
• The phase III trial demonstrated a significantly higher response rate (41.3% vs 16.7%) for pemetrexed/cisplatin compared to cisplatin.
• Pemetrexed/cisplatin improved median survival (12.1 vs 9.3 months) and 1-year survival (50.3% vs 38%) versus cisplatin.
• The combination therapy also showed superiority in quality of life and pulmonary function.

Conclusions:

• Pemetrexed, particularly in combination with cisplatin, offers a significant survival benefit for patients with malignant pleural mesothelioma.
• This combination regimen improves treatment outcomes and patient quality of life compared to cisplatin alone.
• Pemetrexed represents an effective therapeutic option in the management of MPM.